Which has higher valuation and earnings, HCM or RYTM?

HUTCHMED has higher revenue and earnings than Rhythm Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.58 $456.91M N/A N/A Rhythm Pharmaceuticals $189.76M 38.39 -$196.54M -$3.13 N/A

Does the media favor HCM or RYTM?

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat Rhythm Pharmaceuticals' score of 0.34 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MIRM or HCM?

HUTCHMED has higher revenue and earnings than Mirum Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $521.31M 13.70 -$23.36M -$13.61 N/A HUTCHMED $548.51M 3.58 $456.91M N/A N/A

Does the media prefer MIRM or HCM?

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 2 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat HUTCHMED's score of 1.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, LNTH or HCM?

HUTCHMED has lower revenue, but higher earnings than Lantheus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.45 $233.56M $4.15 25.48 HUTCHMED $548.51M 3.58 $456.91M N/A N/A

Is LNTH or HCM more profitable?

Lantheus has a net margin of 18.05% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 29.32% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% HUTCHMED N/A N/A N/A

Does the media prefer LNTH or HCM?

In the previous week, Lantheus had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat Lantheus' score of 0.71 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, COGT or HCM?

HUTCHMED has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A HUTCHMED $548.51M 3.58 $456.91M N/A N/A

Is COGT or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% HUTCHMED N/A N/A N/A

Does the media prefer COGT or HCM?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. HUTCHMED's average media sentiment score of 1.18 beat Cogent Biosciences' score of 0.45 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HCM or PTCT?

PTC Therapeutics has higher revenue and earnings than HUTCHMED. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.58 $456.91M N/A N/A PTC Therapeutics $1.73B 3.77 $682.64M -$2.33 N/A

Does the media favor HCM or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat PTC Therapeutics' score of 0.34 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

HUTCHMED (HCM) Competitors

$11.22 -0.10 (-0.92%)

As of 12:20 PM Eastern

Compare

HCM vs. RYTM, MIRM, LNTH, COGT, and PTCT

Should you buy HUTCHMED stock or one of its competitors? MarketBeat compares HUTCHMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HUTCHMED include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does HUTCHMED compare to Rhythm Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

HUTCHMED has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

HUTCHMED currently has a consensus price target of $15.30, suggesting a potential upside of 35.94%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 30.08%. Given HUTCHMED's higher possible upside, analysts plainly believe HUTCHMED is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat Rhythm Pharmaceuticals' score of 0.34 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has higher revenue and earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.58	$456.91M	N/A	N/A
Rhythm Pharmaceuticals	$189.76M	38.39	-$196.54M	-$3.13	N/A

HUTCHMED has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. HUTCHMED's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

HUTCHMED beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

HUTCHMED has higher revenue and earnings than Mirum Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A
HUTCHMED	$548.51M	3.58	$456.91M	N/A	N/A

Mirum Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $143.40, indicating a potential upside of 22.43%. HUTCHMED has a consensus target price of $15.30, indicating a potential upside of 35.94%. Given HUTCHMED's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

HUTCHMED has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. HUTCHMED's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
HUTCHMED	N/A	N/A	N/A

8.8% of HUTCHMED shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 2 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat HUTCHMED's score of 1.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HUTCHMED beats Mirum Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Lantheus?

Lantheus (NASDAQ:LNTH) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 29.32% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
HUTCHMED	N/A	N/A	N/A

In the previous week, Lantheus had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat Lantheus' score of 0.71 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus target price of $110.43, suggesting a potential upside of 4.44%. HUTCHMED has a consensus target price of $15.30, suggesting a potential upside of 35.94%. Given HUTCHMED's higher probable upside, analysts clearly believe HUTCHMED is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

HUTCHMED has lower revenue, but higher earnings than Lantheus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.45	$233.56M	$4.15	25.48
HUTCHMED	$548.51M	3.58	$456.91M	N/A	N/A

Summary

Lantheus beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. HUTCHMED's average media sentiment score of 1.18 beat Cogent Biosciences' score of 0.45 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
HUTCHMED	N/A	N/A	N/A

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

8.8% of HUTCHMED shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HUTCHMED has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
HUTCHMED	$548.51M	3.58	$456.91M	N/A	N/A

Cogent Biosciences presently has a consensus price target of $45.90, indicating a potential upside of 15.66%. HUTCHMED has a consensus price target of $15.30, indicating a potential upside of 35.94%. Given HUTCHMED's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

HUTCHMED beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

How does HUTCHMED compare to PTC Therapeutics?

HUTCHMED (NASDAQ:HCM) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

HUTCHMED has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. HUTCHMED's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
PTC Therapeutics	-22.58%	-362.45%	-6.76%

8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PTC Therapeutics has higher revenue and earnings than HUTCHMED.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.58	$456.91M	N/A	N/A
PTC Therapeutics	$1.73B	3.77	$682.64M	-$2.33	N/A

HUTCHMED currently has a consensus target price of $15.30, indicating a potential upside of 35.94%. PTC Therapeutics has a consensus target price of $92.29, indicating a potential upside of 17.19%. Given HUTCHMED's higher possible upside, equities research analysts clearly believe HUTCHMED is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, PTC Therapeutics had 5 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat PTC Therapeutics' score of 0.34 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

PTC Therapeutics beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.96B	$3.64B	$6.80B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.63	27.05	24.17
Price / Sales	3.58	304.98	517.90	92.83
Price / Cash	4.02	60.31	26.68	47.25
Price / Book	1.57	8.05	10.65	6.23
Net Income	$456.91M	$23.81M	$3.59B	$331.42M
7 Day Performance	0.04%	-1.53%	-0.84%	-1.22%
1 Month Performance	9.48%	2.16%	1.42%	-1.36%
1 Year Performance	-36.56%	44.29%	24.75%	18.43%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	2.1779 of 5 stars	$11.22 -0.9%	$15.30 +36.4%	-35.6%	$1.96B	$548.51M	N/A	1,796	Positive News
RYTM Rhythm Pharmaceuticals	2.9184 of 5 stars	$106.06 +1.4%	$138.29 +30.4%	+17.3%	$7.27B	$189.76M	N/A	140	News Coverage
MIRM Mirum Pharmaceuticals	3.2352 of 5 stars	$117.13 +0.4%	$143.40 +22.4%	+124.6%	$7.14B	$521.31M	N/A	140
LNTH Lantheus	2.8788 of 5 stars	$105.99 +1.5%	$110.43 +4.2%	+48.8%	$6.90B	$1.55B	25.55	1,193
COGT Cogent Biosciences	1.8164 of 5 stars	$38.99 +1.8%	$45.90 +17.7%	+206.6%	$6.66B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does HUTCHMED compare to Rhythm Pharmaceuticals?

Summary

How does HUTCHMED compare to Mirum Pharmaceuticals?

Summary

How does HUTCHMED compare to Lantheus?

Summary

How does HUTCHMED compare to Cogent Biosciences?

Summary

How does HUTCHMED compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does HUTCHMED compare to Rhythm Pharmaceuticals?

Which has more volatility and risk, HCM or RYTM?

Do analysts prefer HCM or RYTM?

Do insiders and institutionals hold more shares of HCM or RYTM?

Does the media favor HCM or RYTM?

Which has higher valuation and earnings, HCM or RYTM?

Is HCM or RYTM more profitable?

Summary

How does HUTCHMED compare to Mirum Pharmaceuticals?

Which has better valuation & earnings, MIRM or HCM?

Which has more risk & volatility, MIRM or HCM?

Do analysts rate MIRM or HCM?

Is MIRM or HCM more profitable?

Do insiders & institutionals have more ownership in MIRM or HCM?

Does the media prefer MIRM or HCM?

Summary

How does HUTCHMED compare to Lantheus?

Which has more risk and volatility, LNTH or HCM?

Do insiders & institutionals hold more shares of LNTH or HCM?

Is LNTH or HCM more profitable?

Does the media prefer LNTH or HCM?

Do analysts recommend LNTH or HCM?

Which has stronger valuation and earnings, LNTH or HCM?

Summary

How does HUTCHMED compare to Cogent Biosciences?

Does the media prefer COGT or HCM?

Is COGT or HCM more profitable?

Which has more risk & volatility, COGT or HCM?

Do insiders & institutionals believe in COGT or HCM?

Which has higher valuation & earnings, COGT or HCM?

Do analysts rate COGT or HCM?

Summary

How does HUTCHMED compare to PTC Therapeutics?

Is HCM or PTCT more profitable?

Do institutionals & insiders believe in HCM or PTCT?

Which has better valuation and earnings, HCM or PTCT?

Do analysts rate HCM or PTCT?

Does the media favor HCM or PTCT?

Which has more risk & volatility, HCM or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools